| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Hopman Mark | Chief Commercial Officer | C/O BETA BIONICS, INC., 11 HUGHES, IRVINE | /s/ Stephen Feider, Attorney-in-Fact | 04 Jun 2025 | 0002048497 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BBNX | Common Stock | Sale | $4,053 | -238 | -0.68% | $17.03 | 34,762 | 02 Jun 2025 | Direct | F1, F2 |
| transaction | BBNX | Common Stock | Sale | $10,000 | -551 | -1.6% | $18.15 | 34,211 | 02 Jun 2025 | Direct | F1, F3 |
| transaction | BBNX | Common Stock | Sale | $1,477 | -79 | -0.23% | $18.69 | 34,132 | 02 Jun 2025 | Direct | F1, F4 |
| Id | Content |
|---|---|
| F1 | The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. |
| F2 | The weighted average sale price for the transaction reported was $17.028 and the range of prices were between $16.62 and $17.56. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| F3 | The weighted average sale price for the transaction reported was $18.1489 and the range of prices were between $17.62 and $18.60. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| F4 | The weighted average sale price for the transaction reported was $18.691 and the range of prices were between $18.69 and $18.73. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |